Clinical Trial Update: Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating first-line treatment of chronic graft-versus-host disease with ciclosporine, corticosteroids, and rituximab has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• Corticosteroids (corticosteroids)
• Rituximab (rituximab)

Snippet

Sponsor: Nantes University Hospital | Conditions: Graft Versus Host Disease | Phase 2 | Status: COMPLETED